Answers are grounded in this paper and cite their sources.
Together, the data presented suggest that selective targeting of ERβ may be an efficacious stand-alone treatment option and/or become an important add-on to existing malignant mesothelioma therapy.
No takes yet. Share an insight, caveat, or question.
Pinton et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: